Floatz logo

Inotuzumab Ozogamicin

B Lymphoblastic Lymphoma

Alliance for Clinical Trials in Oncologyantibody_drug_conjugatePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the B Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
National Cancer Institute (NCI)
Phase 3BB
Blinatumomab
Children's Oncology Group
Phase 3BB
PREDNISONE TABLETS
Alliance for Clinical Trials in Oncology
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Alliance for Clinical Trials in Oncology
Phase 3BB
METHOTREXATE
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 22 →

Same molecule, other indications

Inotuzumab Ozogamicin is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
CD22 PositiveDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →